Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its ...

The IL-6 receptor antagonist market presents significant opportunities in underexplored areas like thyroid eye disease and atherosclerotic cardiovascular disease (ASCVD). Recent acquisitions and ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it intends to develop its ...

Type 1 diabetes (T1D) is an autoimmune disorder characterized by the specific destruction of insulin-producing pancreatic β-cells.

在上一期的干货中，小恒主要为大家介绍了细胞焦亡的相关理论基础和核心执行者GSDM家族，除了GSDM家族外，另一大名鼎鼎的家族——炎症小体家族的成员们在细胞焦亡中又扮演了什么角色呢？本期文章，我们将为大家介绍这一庞大家族在细胞焦亡中的功能与机制。

New research uncovers the exact immune-to-brain pathway that drives the loss of social motivation during sickness.

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

By Dengyuemed International Business Department  November 28 — The National Medical Products Administration (NMPA) has approved the marketing of picankibart injection, an innovative IL-23p19–targeting ...

Tiziana Life Sciences considers the antibody, known as TZLS-501, to have potential to operate as a standalone business and intends to proceed with steps for a publicly-listed immunology-focused ...

A new study published in the Journal of Cannabis Research and U.S. Library of Medicine reports that cannabidiol may reduce ...